Member of Lyonbiopole
90% of cancer deaths are related to drug resistance which undercuts the efficacy of anti-cancer drugs like inhibitors of MAPK signaling, a pathway hyperactivated in 40% cancers. Another limitation of MAPK Inhibitors is their inability to cure rare diseases caused by MAPK-activating mutations.
To overcome these limitations, TheraPPI develop drugs inducing signal dysregulation instead of signal inhibition. Our two first programs target a MAPK protein interaction discovered by the founder team.
Application market: Immune, AutoIm & Inflam. diseases, Oncology, Rare disease
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Small Molecules
Created on jan. 11th, 2023 - 2 employees
Address
28 Rue Laennec
CENTRE LEON BERARD
69008 LYON
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.